Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$6.93
-0.26 (-3.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-24.8M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.8%
↓Gross Margin
-2.8%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-42.6%
FCF CAGR
—
FCF margin
31.8%
FCF / Net income
-0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $798.1M · net income $-1.37B · FCF $253.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $798.1M | $798.1M | $2.71B | $3.14B | $4.22B |
| Net Income | $-1.37B | $-1.37B | $438.2M | $472.7M | $185.4M |
| EBITDA | $-1.31B | $-1.31B | $804.6M | $804.2M | $606.2M |
| EPS | -1.45 | -1.45 | 0.47 | 0.50 | 0.20 |
| Gross Margin | -2.8% | -2.8% | 55.1% | 42.4% | 17.7% |
| Operating Margin | -52.4% | -52.4% | 31.7% | 8.1% | 8.5% |
| Net Margin | -171.2% | -171.2% | 16.2% | 15.0% | 4.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.42 | 0.42 | 0.41 |
| Current Ratio | 1.38 | 1.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $253.6M | $253.6M | $-24.8M | $-573.4M | $-731.1M |
| Returns | |||||
| ROE | -21.8% | -21.8% | 5.6% | 6.3% | 2.6% |
| Valuation | |||||
| P/E | — | — | 24.43 | 24.24 | 67.51 |
| EV/EBITDA | — | — | 16.09 | 16.36 | 23.83 |
| P/B | 1.04 | 1.04 | 1.37 | 1.52 | 1.76 |
| Growth & Yield | |||||
| Revenue Growth | -70.5% | -70.5% | -13.9% | -25.5% | — |
| EPS Growth | -411.9% | -411.9% | -7.3% | 155.3% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.47 → -1.45
Residual
-39.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.